ContraFect is a biotechnology business based in the US. ContraFect shares (CFRX) are listed on the NASDAQ and all prices are listed in US Dollars. ContraFect employs 23 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $0.60 |
|---|---|
| 52-week range | $0.51 - $15.94 |
| 50-day moving average | $0.98 |
| 200-day moving average | $3.25 |
| Wall St. target price | $5.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-835.02 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.595 from 2023-09-22
| 1 week (2023-09-18) | 1.02% |
|---|---|
| 1 month (2023-08-25) | -17.12% |
| 3 months (2023-06-23) | -58.97% |
| 6 months (2023-03-24) | -71.39% |
| 1 year (2022-09-23) | 237.30% |
|---|---|
| 2 years (2021-09-24) | -85.16% |
| 3 years (2020-09-25) | 5.15 |
| 5 years (2018-09-25) | 19.1 |
| Gross profit TTM | $-1,606,434 |
|---|---|
| Return on assets TTM | -78.51% |
| Return on equity TTM | -608.75% |
| Profit margin | 0% |
| Book value | $-0.10 |
| Market Capitalization | $6.3 million |
TTM: trailing 12 months
We're not expecting ContraFect to pay a dividend over the next 12 months.
ContraFect's shares were split on a 1:80 basis on 14 February 2023. So if you had owned 80 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ContraFect shares – just the quantity. However, indirectly, the new 7900% higher share price could have impacted the market appetite for ContraFect shares which in turn could have impacted ContraFect's share price.
Over the last 12 months, ContraFect's shares have ranged in value from as little as $0.51 up to $15.944. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ContraFect's is 0.4879. This would suggest that ContraFect's shares are less volatile than average (for this exchange).
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens.
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.